top of page
Continuing COVID-19 vaccine research is important to address variants
of concern and to develop effective, low-cost vaccines

Our Project


Our project aims to produce and test new mucosal vaccine candidates, using probiotic bacteria as a delivery vector, against the emerging known variants of the SARS-CoV-2 virus to:
(1) tackle these variants
(2) as case studies for developing a generic technology that will allow us to very rapidly adapt to almost any variant emerging in the future.


Our technology is GMO-free, as the vaccine consists of common food grade Lactobacillus, which carries the viral antigen allowing it to elicit a protective immune response in the host.

Mucosal vaccination, i.e., the administration of the viral antigen without intramuscular injection, but, instead, orally or via nasal spray, may represent a new, efficient, more acceptable method of vaccine administration, although not yet explored with SARS-CoV-2.
bottom of page